Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

(University of Colorado Denver) A study presented at the American Society of Clinical Oncology Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).